Table 1.

FDA approved dosing regimens for NOACs based on indication [8–11]

Medication	Indication	Dosea
Dabigatran	Stroke and systemic embolism prophylaxis in NVAF	150 mg PO BID
	VTE prophylaxis for recurrent VTE	150 mg PO BID
	VTE treatment	150 mg PO BID (5–10 days after parenteral anticoagulants)
Rivaroxaban	Stroke and systemic embolism prophylaxis in NVAF	20 mg PO with evening meal
	VTE prophylaxis for recurrent VTE	20 mg PO daily with evening meal
	VTE treatment	15 mg PO BID × 21 days, then 20 mg PO daily with food
	VTE prophylaxis for THA or TKA surgery	10 mg PO daily × 35 days (THA) 10 mg PO daily × 12 days (TKA)
Apixaban	Stroke and systemic embolism prophylaxis in NVAF	5 mg PO BID
	VTE prophylaxis for recurrent VTE	2.5 mg PO BID
	VTE treatment	10 mg PO BID × 7 days, then 5 mg PO BID
	VTE prophylaxis for THA or TKA surgery	2.5 mg PO BID × 35 days (THA) 2.5 mg PO BID × 12 days (TKA)
Edoxaban	Stroke and systemic embolism prophylaxis in NVAF	60 mg PO daily
	VTE treatment	60 mg PO daily (5–10 days after parenteral anticoagulants)

BID twice daily, FDA Food and Drug Administration, NOAC non-vitamin K oral anticoagulants, NVAF non-valvular atrial fibrillation, THA total-hip arthroplasty, TKA total-knee arthroplasty, PO by mouth, VTE venous thromboembolism

^aRefer to package inserts for dose adjustments based on patient age, weight, and renal function